

MAR 21 2005

---

**FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY**

---

March 21, 2005

TO: Examiner Maryam Monshipouri  
Group 1652  
571-272-0932

FROM Justin D. Karjala  
Celera Genomics Corp.  
(240) 453-3812

FAX NO: (703) 872-9306

# OF PAGES (incl. cover): 6

---

Re: U.S. Serial No. 10/730,010, filed December 9, 2003  
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID  
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES  
THEREOF"  
Atty. Docket No.: CL001212CIP-DIVII

A Response to Office Action and a Terminal Disclaimer with fee (please charge the fee for the Terminal Disclaimer to Deposit Account No. 50-0970) in the above-identified application follows.

---

*The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.*

RECEIVED  
CENTRAL FAX CENTER

MAR 21 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Marion WEBSTER et al.

Serial No.: 10/730,010

Filed: December 9, 2003

For: ISOLATED HUMAN KINASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING  
HUMAN KINASE PROTEINS, AND USES  
THEREOF

Art Unit: 1652

Examiner: M. Monshipouri

Atty. Docket: CL001212CIP-DIVII

**RESPONSE TO OFFICE ACTION**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

This is in response to an Office Action from Examiner Monshipouri mailed on December 20, 2004 for the above referenced application. Applicants respectfully request reconsideration of the above-referenced patent application in view of the following remarks.